Edap Tms (NASDAQ:EDAP) used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company’s Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and future indications.
Chief Executive Officer Ryan Rhodes said the newly announced FocalTherics identity combines “focal therapy” and “therapeutics” and reflects a strategic focus on robotic focal therapy. Rhodes said the company’s recent growth has been driven primarily by its HIFU business, while non-core businesses, including ESWL and distribution, have declined.
